Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir

The effect of treatment with favipiravir, an antiviral purine nucleoside analog, for coronavirus disease 2019 (COVID-19) on the production and duration of neutralizing antibodies for SARS-CoV-2 was explored. There were 17 age-, gender-, and body mass index-matched pairs of favipiravir treated versus...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinada, Kanako, Sato, Takashi, Moriyama, Saya, Adachi, Yu, Shinoda, Masahiro, Ota, Shinichiro, Morikawa, Miwa, Mineshita, Masamichi, Matsumura, Takayuki, Takahashi, Yoshimasa, Shinkai, Masaharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024984/
https://www.ncbi.nlm.nih.gov/pubmed/35458400
http://dx.doi.org/10.3390/v14040670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024984/
https://www.ncbi.nlm.nih.gov/pubmed/35458400
http://dx.doi.org/10.3390/v14040670

Ejemplares similares